+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Direct-to-Consumer Genetic Testing Market by Ancestry Testing, Health Risk Testing, Trait Testing, Nutritional And Fitness Testing, Pharmacogenomic Testing, Paternity Testing - Global Forecast to 2030- Product Image
Direct-to-Consumer Genetic Testing Market by Ancestry Testing, Health Risk Testing, Trait Testing, Nutritional And Fitness Testing, Pharmacogenomic Testing, Paternity Testing - Global Forecast to 2030- Product Image
Sale

Direct-to-Consumer Genetic Testing Market by Ancestry Testing, Health Risk Testing, Trait Testing, Nutritional And Fitness Testing, Pharmacogenomic Testing, Paternity Testing - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968843
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Direct-to-Consumer Genetic Testing Market grew from USD 2.36 billion in 2024 to USD 2.79 billion in 2025. It is expected to continue growing at a CAGR of 17.26%, reaching USD 6.16 billion by 2030.

Navigating the Surge of Consumer-Driven Genetic Insights

Direct-to-consumer genetic testing has transcended novelty status to become a mainstream tool for personal health management and ancestral discovery. What began as a niche service offering basic ancestry insights has evolved into a sophisticated ecosystem where consumers can access information on disease risk, drug response, and lifestyle traits from the comfort of their homes. Rapid declines in sequencing and genotyping costs, paired with intuitive digital platforms, have democratized access to DNA analysis and sparked unprecedented curiosity among end users.

This executive summary provides a concise yet comprehensive overview of the forces shaping this dynamic market. It outlines technological breakthroughs, regulatory shifts, and the impact of recent U.S. import tariffs, before unpacking the diverse segment structure and regional dynamics that define consumer demand. We then profile the leading companies driving innovation and offer strategic recommendations that industry leaders can implement today to future-proof their offerings. Finally, our transparent research methodology ensures confidence in the findings and underlines the rigor behind every insight.

Unraveling the Evolution of the DTC Genetic Testing Market

The direct-to-consumer genetic testing market has undergone a profound transformation driven by breakthroughs in sequencing technology and data analytics. Sequencing platforms have matured to deliver high-accuracy results in a fraction of the time and cost that once defined large-scale research laboratories. Artificial intelligence and machine-learning algorithms now interpret complex genomic data to deliver personalized health risk profiles, enabling consumers to make informed decisions about nutrition, fitness, and medical screening.

Concurrent shifts in consumer behavior have amplified demand for actionable insights that extend beyond ancestral origins. Mobile applications and cloud-based dashboards offer real-time updates, trend tracking, and social sharing functionalities that have turned genetic data into an interactive experience. Regulatory frameworks in major markets have also evolved, with transparent guidelines on data privacy and consent ensuring consumer trust while maintaining room for innovation. Strategic partnerships among biotechnology firms, healthcare providers, and retail chains have further expanded distribution channels, ushering in an era where genetic insights are seamlessly integrated into everyday life.

Assessing the Ripple Effects of Recent U.S. Import Tariffs

In 2025, the introduction of new U.S. import tariffs on genetic testing kits and critical reagents has introduced a fresh complexity to the market landscape. Suppliers reliant on trans-Pacific channels have seen cost inflation in raw materials, resulting in upward pressure on per-kit pricing. Companies with vertically integrated manufacturing capabilities in North America have fared better, shielding themselves from full tariff pass-through and reinforcing the competitive advantage of localized production.

The ripple effects extend into global supply chains, prompting diagnostic providers to diversify sourcing strategies and negotiate long-term agreements with domestic and nearshore suppliers. In response, several market participants are exploring the reconfiguration of assembly plants and investing in automation to offset tariff-induced cost increases. While short-term margins may tighten, these strategic shifts position industry players to deliver more resilient operations and maintain price competitiveness as the regulatory environment continues to evolve.

Deconstructing Market Segments to Illuminate Consumer Needs

The market’s segmentation reveals the nuanced ways consumers engage with genetic information across multiple testing categories. Within ancestry testing, consumers choose between autosomal, mitochondrial, and Y-chromosome panels to trace lineage from recent centuries to deep maternal or paternal lines. Health risk testing bifurcates into monogenic disease risk assessments-covering carrier screening and single gene analyses-and polygenic assessments that focus on cardiovascular risk profiles and oncology predispositions. Trait testing expands personalization into daily life, offering insights into behavioral patterns such as sleep quality and stress response, physical characteristics like eye and hair color, and wellness factors including caffeine metabolism and vitamin absorption.

Beyond these dimensions, nutritional and fitness testing enables individuals to optimize training through endurance profiling and muscle performance metrics while identifying nutrient deficiencies such as mineral shortfalls or vitamin D insufficiency. Pharmacogenomic testing addresses personalized drug response across cardiovascular, oncology, and psychiatric medications, the latter evaluating antidepressant and antipsychotic efficacy. Finally, paternity testing serves postnatal and prenatal needs, providing definitive parentage analysis for consumers seeking family planning clarity. Together, these layers of segmentation guide product innovation and marketing strategies that meet highly specific consumer demands.

Regional Dynamics Shaping the Genetic Testing Landscape

Geographic dynamics exert a significant influence on adoption rates and growth potential in the direct-to-consumer genetic testing domain. In the Americas, the United States leads with robust internet penetration, favorable reimbursement policies, and widespread consumer awareness. Markets in Canada and Latin America are catching up, fueled by increasing healthcare digitization and government initiatives aimed at preventive medicine. Regulatory bodies have established clear pathways for test approvals, enabling rapid product launches and fostering healthy competition.

Across Europe, the Middle East, and Africa, mature Western European markets exhibit steady growth underpinned by stringent data privacy regulations that bolster consumer confidence. The United Kingdom and Germany stand out for strong collaborations between biotech firms and public health agencies. In contrast, emerging markets in Eastern Europe and the GCC show early signs of market entry, driven by rising incomes and healthcare infrastructure investments. Meanwhile, Asia-Pacific displays a dual character: established players in Japan, South Korea, and Australia benefit from advanced healthcare systems, while high-growth potential regions such as China, India, and Southeast Asia attract partnerships between local labs and global testing operators.

Profiling Leading Innovators and Market Disruptors

Leadership in direct-to-consumer genetic testing is characterized by a blend of innovation, scale, and consumer engagement strategies. Several pioneers have scaled operations to serve millions of users worldwide, leveraging proprietary genotyping arrays and large reference databases to refine their accuracy. These incumbents complement core offerings with subscription-based wellness programs, telehealth consultations, and mobile applications that foster long-term customer relationships.

Emerging disruptors differentiate through hyper-specialized panels, such as deep polygenic risk models or targeted pharmacogenomic profiles, and by forging B2B partnerships with healthcare systems and life sciences companies. Investment firms have backed a wave of startups specializing in privacy-centric protocols, blockchain-enabled data security, and integrated nutrition-fitness-wellness platforms. This dynamic environment underscores the importance of differentiation through technological ecosystems, strategic alliances, and consumer trust initiatives.

Strategic Imperatives for Industry Advancement

To maintain and accelerate growth, industry leaders should enhance vertically integrated supply chains and consider strategic nearshoring to mitigate tariff risks. Investing in modular manufacturing facilities equipped with automation will reduce per-kit costs and preserve margin integrity. Companies must also prioritize data governance frameworks that exceed regulatory requirements, establishing consumer trust as a core brand attribute.

Expanding into adjacent geographies through strategic licensing or joint ventures can unlock new revenue streams, particularly in high-growth Asia-Pacific and emerging Middle East markets. Product roadmaps should incorporate advanced analytics to deliver predictive insights and tailor subscription models around personalized health journeys. Finally, fostering cross-industry alliances with fitness, nutrition, and telemedicine providers will create comprehensive ecosystems that deepen customer engagement and drive recurring revenue.

Rigorous Framework Underpinning Our Analysis

This analysis is grounded in a multi-stage research framework combining primary and secondary data collection. Primary insights were obtained through interviews with subject-matter experts, including geneticists, laboratory executives, and regulatory consultants. Secondary research encompassed a review of peer-reviewed journals, industry white papers, regulatory filings, and company disclosures. Quantitative data were triangulated from public financial statements, trade databases, and proprietary proprietary datasets on test volumes and pricing trends.

Analytical methodologies included segmentation analysis, PESTEL evaluation, competitive benchmarking, and scenario modeling to assess tariff impacts. Qualitative assessments were synthesized through SWOT analyses and thematic coding of stakeholder interviews. Our approach ensures that all conclusions are underpinned by verifiable evidence and objective rigor, offering reliable guidance to decision-makers.

Synthesizing Insights to Guide Strategic Decisions

The direct-to-consumer genetic testing market sits at the intersection of technological innovation, regulatory evolution, and shifting consumer expectations. Our findings illustrate how advanced sequencing technologies and AI-driven analytics have expanded test portfolios beyond ancestry to encompass health, fitness, wellness, and pharmacogenomics. The recent U.S. tariffs have injected short-term cost challenges, yet they also catalyze supply chain resilience and domestic manufacturing investments.

Segmentation and regional analyses underscore the importance of tailored strategies that align with specific consumer needs and regulatory landscapes. Leading companies differentiate through ecosystem integration, data security, and strategic partnerships. By implementing the recommendations outlined in this report, stakeholders can harness emerging opportunities, mitigate risks, and secure sustainable growth in a market defined by rapid change and immense potential.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Ancestry Testing
    • Autosomal
    • Mitochondrial
    • Y-Chromosome
  • Health Risk Testing
    • Monogenic Disease Risk
      • Carrier Screening
      • Single Gene Tests
    • Polygenic Disease Risk
      • Cardiovascular Risk
      • Oncology Risk
  • Trait Testing
    • Behavioral Traits
      • Sleep Patterns
      • Stress Response
    • Physical Traits
      • Eye Color
      • Hair Color
    • Wellness Traits
      • Caffeine Metabolism
      • Vitamin Absorption
  • Nutritional And Fitness Testing
    • Fitness Optimization
      • Endurance Profiling
      • Muscle Performance
    • Nutrient Deficiency
      • Mineral Deficiency
      • Vitamin D Deficiency
  • Pharmacogenomic Testing
    • Cardiovascular Drugs
    • Oncology Drugs
    • Psychiatric Drugs
      • Antidepressants
      • Antipsychotics
  • Paternity Testing
    • Postnatal
    • Prenatal
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • 23andMe, Inc.
  • Ancestry.com LLC
  • MyHeritage Ltd.
  • Gene by Gene, Ltd.
  • Living DNA Ltd.
  • Vitagene, Inc.
  • Nebula Genomics, Inc.
  • Prenetics Ltd.
  • Orig3n, Inc.
  • Dante Labs S.p.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Direct-to-Consumer Genetic Testing Market, by Ancestry Testing
8.1. Introduction
8.2. Autosomal
8.3. Mitochondrial
8.4. Y-Chromosome
9. Direct-to-Consumer Genetic Testing Market, by Health Risk Testing
9.1. Introduction
9.2. Monogenic Disease Risk
9.2.1. Carrier Screening
9.2.2. Single Gene Tests
9.3. Polygenic Disease Risk
9.3.1. Cardiovascular Risk
9.3.2. Oncology Risk
10. Direct-to-Consumer Genetic Testing Market, by Trait Testing
10.1. Introduction
10.2. Behavioral Traits
10.2.1. Sleep Patterns
10.2.2. Stress Response
10.3. Physical Traits
10.3.1. Eye Color
10.3.2. Hair Color
10.4. Wellness Traits
10.4.1. Caffeine Metabolism
10.4.2. Vitamin Absorption
11. Direct-to-Consumer Genetic Testing Market, by Nutritional And Fitness Testing
11.1. Introduction
11.2. Fitness Optimization
11.2.1. Endurance Profiling
11.2.2. Muscle Performance
11.3. Nutrient Deficiency
11.3.1. Mineral Deficiency
11.3.2. Vitamin D Deficiency
12. Direct-to-Consumer Genetic Testing Market, by Pharmacogenomic Testing
12.1. Introduction
12.2. Cardiovascular Drugs
12.3. Oncology Drugs
12.4. Psychiatric Drugs
12.4.1. Antidepressants
12.4.2. Antipsychotics
13. Direct-to-Consumer Genetic Testing Market, by Paternity Testing
13.1. Introduction
13.2. Postnatal
13.3. Prenatal
14. Americas Direct-to-Consumer Genetic Testing Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Direct-to-Consumer Genetic Testing Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Direct-to-Consumer Genetic Testing Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. 23andMe, Inc.
17.3.2. Ancestry.com LLC
17.3.3. MyHeritage Ltd.
17.3.4. Gene by Gene, Ltd.
17.3.5. Living DNA Ltd.
17.3.6. Vitagene, Inc.
17.3.7. Nebula Genomics, Inc.
17.3.8. Prenetics Ltd.
17.3.9. Orig3n, Inc.
17.3.10. Dante Labs S.p.A.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DIRECT-TO-CONSUMER GENETIC TESTING MARKET MULTI-CURRENCY
FIGURE 2. DIRECT-TO-CONSUMER GENETIC TESTING MARKET MULTI-LANGUAGE
FIGURE 3. DIRECT-TO-CONSUMER GENETIC TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DIRECT-TO-CONSUMER GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DIRECT-TO-CONSUMER GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIRECT-TO-CONSUMER GENETIC TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY AUTOSOMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MITOCHONDRIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY Y-CHROMOSOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY SINGLE GENE TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR RISK, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ONCOLOGY RISK, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY SLEEP PATTERNS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY STRESS RESPONSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY EYE COLOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HAIR COLOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CAFFEINE METABOLISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY VITAMIN ABSORPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ENDURANCE PROFILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MUSCLE PERFORMANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MINERAL DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY VITAMIN D DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ONCOLOGY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POSTNATAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PRENATAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 81. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 82. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 83. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 84. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 85. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 86. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 87. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 88. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 89. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 90. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 91. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 92. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 93. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 94. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 95. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 96. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 97. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 98. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 99. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 100. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 104. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 105. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 106. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 107. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 166. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 167. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 168. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 169. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 170. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 171. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 172. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 173. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 174. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 175. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 176. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 177. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 178. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 179. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 180. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 181. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 182. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 183. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 184. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 185. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 186. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 187. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 188. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 189. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 190. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 191. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 192. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 193. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 208. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 209. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 210. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 211. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 212. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 213. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 214. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 215. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 216. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 217. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 218. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 219. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 220. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 221. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 222. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 223. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 224. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 225. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 226. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 227. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 228. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 229. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 230. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 231. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 232. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 233. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 234. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 235. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY POLYGENIC DISEASE RISK, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAIT TESTING, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BEHAVIORAL TRAITS, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHYSICAL TRAITS, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS TRAITS, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRITIONAL AND FITNESS TESTING, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FITNESS OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NUTRIENT DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMIC TESTING, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PSYCHIATRIC DRUGS, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY PATERNITY TESTING, 2018-2030 (USD MILLION)
TABLE 278. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY TESTING, 2018-2030 (USD MILLION)
TABLE 279. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEALTH RISK TESTING, 2018-2030 (USD MILLION)
TABLE 280. DENMARK DIRECT-TO-CONSUMER GEN

Companies Mentioned

The companies profiled in this Direct-to-Consumer Genetic Testing market report include:
  • 23andMe, Inc.
  • Ancestry.com LLC
  • MyHeritage Ltd.
  • Gene by Gene, Ltd.
  • Living DNA Ltd.
  • Vitagene, Inc.
  • Nebula Genomics, Inc.
  • Prenetics Ltd.
  • Orig3n, Inc.
  • Dante Labs S.p.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.79 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.16 Billion
Compound Annual Growth Rate17.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Direct-To-Consumer (DTC) Genetic Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Direct-To-Consumer (DTC) Genetic Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Direct-to-consumer DNA Genetic Testing Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Direct-to-consumer DNA Genetic Testing Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 89 Pages
  • Global
From
Genetic Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR-based Testing, Array Technology), By Application, By Product, By Channel (Online, Offline), By End-use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Genetic Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR-based Testing, Array Technology), By Application, By Product, By Channel (Online, Offline), By End-use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Direct-to-Consumer (DTC) Genetic Testing - Global Strategic Business Report - Product Image

Direct-to-Consumer (DTC) Genetic Testing - Global Strategic Business Report

  • Report
  • 324 Pages
  • Global
From
Predictive Genetic Testing and Consumer Genomics Market Size, Share & Trends Analysis Report by Test, Application, Setting (DTC, Professional), Region, and Segment Forecasts, 2025-2030 - Product Image

Predictive Genetic Testing and Consumer Genomics Market Size, Share & Trends Analysis Report by Test, Application, Setting (DTC, Professional), Region, and Segment Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From

About the Direct to Consumer Genetic Testing Market

Direct to Consumer Genetic Testing (DTCGT) is a type of genetic testing that allows individuals to access their genetic information without the need for a doctor or other healthcare provider. DTCGT companies provide genetic testing services directly to consumers, typically through a simple saliva sample. The results of the test can provide insight into an individual's ancestry, health risks, and other genetic traits. The DTCGT market has grown rapidly in recent years, driven by advances in genomics technology and the increasing availability of affordable testing services. Consumers are increasingly turning to DTCGT to gain access to their genetic information and to learn more about their health and ancestry. Some of the leading companies in the DTCGT market include 23andMe, AncestryDNA, Helix, and MyHeritage. These companies offer a range of services, from ancestry testing to health risk assessments. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.